Last reviewed · How we verify
NCT05491369
Effectiveness of an Epilepsy Application for Self-management in Viet Nam
NA trial testing Epilepsy application in Epilepsy in 148 participants. Completed in 1 June 2024.
30 December 2023
Quick facts
| Lead sponsor | University of Medicine and Pharmacy at Ho Chi Minh City |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 148 |
| Start date | 1 September 2022 |
| Primary completion | 30 December 2023 |
| Estimated completion | 1 June 2024 |
| Sites | 2 locations across Vietnam |
Drugs / interventions tested
- Epilepsy application
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Who can join
18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Epilepsy is a common neurological disease which effects all genders, ages and geographic regions. Self-management refers to "the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences of health conditions". Optimal self-management may improve self-efficacy, knowledge about epilepsy of people with epilepsy (PWE) and family, medical compliance and avoidance of seizure triggers. This study aims to determine the effectiveness of the epilepsy app for PWE to improve self-management
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05491369
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other University of Medicine and Pharmacy at Ho Chi Minh City trials
Trials by the same sponsor.
- NCT07530042 — Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain. · NA · not yet recruiting
- NCT07537439 — Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis · NA · not yet recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT07520071 — "Xuong Tan Lac Than" Exercise for Range of Motion and Muscle Endurance · NA · recruiting
- NCT07487181 — A Survey of Traditional Medicine Pattern Identification in Patients With Erectile Dysfunction · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05491369 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Medicine and Pharmacy at Ho Chi Minh City
- Last refreshed: 13 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491369.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing